Hologic, Inc. $HOLX Shares Bought by Cromwell Holdings LLC

Cromwell Holdings LLC grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 307.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 578 shares of the medical equipment provider’s stock after buying an additional 436 shares during the quarter. Cromwell Holdings LLC’s holdings in Hologic were worth $38,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of HOLX. Procyon Advisors LLC acquired a new stake in Hologic in the first quarter valued at $692,000. Clean Yield Group increased its holdings in shares of Hologic by 15.9% in the 1st quarter. Clean Yield Group now owns 52,909 shares of the medical equipment provider’s stock valued at $3,268,000 after purchasing an additional 7,263 shares in the last quarter. Washington Capital Management Inc. lifted its stake in shares of Hologic by 94.8% in the first quarter. Washington Capital Management Inc. now owns 15,445 shares of the medical equipment provider’s stock valued at $954,000 after purchasing an additional 7,515 shares during the period. Wedge Capital Management L L P NC boosted its holdings in Hologic by 37.0% during the first quarter. Wedge Capital Management L L P NC now owns 625,928 shares of the medical equipment provider’s stock worth $38,664,000 after buying an additional 168,889 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its position in Hologic by 22.3% during the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 335 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Up 0.5%

Shares of NASDAQ:HOLX opened at $68.22 on Friday. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $15.17 billion, a P/E ratio of 28.31, a P/E/G ratio of 2.33 and a beta of 0.63. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The stock’s fifty day simple moving average is $66.97 and its 200-day simple moving average is $63.08.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday. Evercore ISI raised their price objective on Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a research note on Tuesday, July 8th. Stephens reiterated an “overweight” rating and set a $78.00 target price on shares of Hologic in a research report on Thursday, September 18th. Morgan Stanley upped their target price on Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. Finally, Mizuho set a $75.00 price target on Hologic in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.38.

Insider Buying and Selling at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.88% of the stock is currently owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.